M-VEC (methotrexate, vinblastine, epidoxorubicin and cisplatin), a new combined drug regimen in which epidoxorubicin has been substituted to adriamycin to reduce the toxicity of the original M-VAC chemotherapy, has been tested in 23 patients with locally advanced transitional cell bladder cancer (TCBC) (stage T2-T4 N(o) M(o). After two to four courses, an objective response was observed in 19 patients, with 13 clinical complete responses. Seven patients underwent cystectomy after chemotherapy: one patient had no residual tumor on bladder specimens, rive patients had a surgical eradication of the disease, while one patient had only a partial resection. Eight relapses of bladder carcinoma were observed, three among the surgically treated patients and five among patients who did not undergo cystectomy, with a median time-to-relapse of 9.7 months. Progression-free survival at 24 months was 52.3%. M-VEC regimen appears to be effective in locally advanced TCBC, with acceptable toxicity.
|Data di pubblicazione:||1991|
|Titolo:||METHOTREXATE, VINBLASTINE, EPIDOXORUBICIN AND CISPLATIN (M-VEC) IN PATIENTS WITH LOCALLY ADVANCED TRANSITIONAL BLADDER-CANCER|
|Autori:||Frassoldati, A; Federico, Massimo; Barbieri, F; Brausi, M; Pollastri, C; Berri, G; Castagnetti, G; Palladini, Pp; Silingardi, Vittorio|
|Digital Object Identifier (DOI):||10.1007/BF02988861|
|Appare nelle tipologie:||Articolo su rivista|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris